List of Excipients in Branded Drug PEMETREXED DIPOTASSIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Avyxa Pharma LLC	PEMETREXED DIPOTASSIUM	pemetrexed dipotassium	83831-111	HYDROCHLORIC ACID
Avyxa Pharma LLC	PEMETREXED DIPOTASSIUM	pemetrexed dipotassium	83831-111	MANNITOL

Pemetrexed Dipotassium Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

Pemetrexed dipotassium is a potential alternative salt form for an established oncology active ingredient, but its commercial value depends on regulatory positioning rather than salt selection alone. The reference product, Alimta, uses pemetrexed disodium. FDA-approved generic products also generally use pemetrexed disodium, mannitol, hydrochloric acid, sodium hydroxide, and sterile water for injection after reconstitution. A pemetrexed dipotassium product could create opportunities in injectable formulation, ready-to-use oncology supply, global API sourcing, and differentiated stability profiles, but it would require a salt-specific regulatory and equivalence strategy.

What is pemetrexed dipotassium and how does it compare with pemetrexed disodium?

Pemetrexed dipotassium is a salt of pemetrexed, an antifolate anticancer agent approved primarily for mesothelioma and non-small-cell lung cancer. The marketed reference product contains pemetrexed disodium, not pemetrexed dipotassium.[1]

Attribute	Pemetrexed disodium	Pemetrexed dipotassium
Active moiety	Pemetrexed	Pemetrexed
Approximate molecular weight	471.4 g/mol	503.6 g/mol
Counterion	2 sodium ions	2 potassium ions
Established U.S. reference product	Yes	No identified reference product
Common dosage form	Lyophilized powder for injection	Potentially lyophilized powder, concentrate, or ready-to-use solution
Primary regulatory route for a generic	ANDA referencing pemetrexed injection	Likely requires salt-specific regulatory justification
Main formulation concern	Sodium load, pH, reconstitution stability	Potassium load, pH, ionic strength, compatibility
Biosimilar exposure	None	None

The active moiety is the same, but the salt is not interchangeable for regulatory purposes without supporting data. Salt conversion changes molecular weight, ionization behavior, osmolality, crystallinity, hygroscopicity, dissolution, pH, and potentially degradation pathways.

At a 500 mg pemetrexed dose, the theoretical potassium content of the dipotassium salt is approximately 77.6 mg, or 1.99 mmol of potassium. The amount is modest after dilution, but the product would require accurate labeling and assessment for patients with renal impairment, hyperkalemia risk, or concurrent potassium-retaining therapy.

What is the FDA regulatory status of pemetrexed dipotassium?

No FDA-approved reference product identified in the Orange Book is based on pemetrexed dipotassium. Alimta and established generic injections are based on pemetrexed disodium.[1,2]

Pemetrexed dipotassium would likely fall into one of three regulatory categories:

1. An API salt used in an injectable drug product under an ANDA, if FDA accepts the formulation as pharmaceutically equivalent and therapeutically equivalent to the reference product.
2. A 505(b)(2) product if the salt, dosage form, route, or clinical presentation requires reliance on FDA findings for pemetrexed but includes material differences from the listed drug.
3. A non-U.S. product governed by national rules for salt selection, abridged applications, or hybrid applications.

The principal regulatory risk is that a different salt may not qualify as a routine generic substitution. The sponsor would need to establish pharmaceutical equivalence, active-moiety equivalence, impurity control, stability, reconstitution performance, and clinical relevance of the counterion. FDA’s ANDA guidance treats formulation composition, dosage form, strength, route, and active ingredient identity as core equivalence considerations.[3]

What FDA data would be important for a dipotassium injectable?

A commercial filing would typically require:

• Salt identity and structural characterization.
• Assay and related-substance methods.
• Elemental potassium quantification.
• pH and osmolality data.
• Reconstitution time and solution appearance.
• Particulate matter and sterility data.
• Container-closure integrity.
• Extractables and leachables.
• Compatibility with infusion bags, tubing, and common diluents.
• Photostability and temperature-excursion data.
• Comparative stability against the disodium product where relevant.
• Justification for the proposed dosage strength and dosing expression.

ICH Q8 and Q1A principles support a formulation-development program based on critical material attributes, critical process parameters, degradation pathways, and defined stability conditions.[4,5]

What excipients are used in existing pemetrexed injection products?

Existing pemetrexed injection products are usually lyophilized powders containing pemetrexed disodium and mannitol. Hydrochloric acid and sodium hydroxide are used for pH adjustment. The reconstitution diluent is generally preservative-free 0.9% sodium chloride injection.[1,6]

Formulation element	Commercial function	Relevance to pemetrexed dipotassium
Mannitol	Bulking agent and cake former in lyophilization	Can support cake structure, but concentration may need optimization for a different salt
Hydrochloric acid	pH adjustment	May alter chloride load and local ionic strength
Sodium hydroxide	pH adjustment	Can create mixed potassium-sodium counterion conditions if used in excess
Water for injection	Reconstitution medium	Standard sterile diluent
Sodium chloride injection	Final dilution medium	Affects osmolality and compatibility
Nitrogen headspace, where used	Oxygen reduction	May reduce oxidative degradation risk
Container-closure system	Moisture and oxygen barrier	Important for a hygroscopic potassium salt

The strongest initial strategy is a conservative, lyophilized formulation using a limited excipient set. This approach minimizes new toxicology concerns, simplifies extractables evaluation, and aligns with established oncology injectable manufacturing.

What excipient strategy is most attractive for pemetrexed dipotassium?

Lyophilized vial strategy

A lyophilized vial is the most defensible first commercial platform. It can address solid-state stability, reduce hydrolysis during storage, and fit hospital oncology workflows.

The development program should screen:

• Mannitol concentration and crystallization behavior.
• pH before and after lyophilization.
• Residual moisture.
• Primary drying temperature and collapse temperature.
• Reconstitution time.
• Solution clarity and particulate formation.
• Potassium-related pH drift.
• Stability after reconstitution and dilution.

A formulation using mannitol alone is attractive because it is already familiar in pemetrexed products. The limitation is that a dipotassium salt may have different crystallization and moisture behavior from pemetrexed disodium. Mannitol may therefore require adjustment in concentration or a secondary bulking or stabilizing excipient.

Ready-to-use solution strategy

A ready-to-use or concentrated solution could reduce preparation steps and occupational handling in oncology pharmacies. It would also create a stronger product-differentiation position than a conventional vial.

The main technical barriers are:

• Long-term solution stability.
• Oxidation and hydrolysis.
• Adsorption to infusion components.
• Precipitation after dilution.
• Container-closure compatibility.
• Preservative suitability.
• Microbial control.
• Higher shipping and storage sensitivity.

A single-dose, preservative-free solution in a ready-to-administer bag or vial is commercially more credible than a multidose preserved product. Cytotoxic injectable products face stringent sterility and handling requirements, and preservatives may complicate tolerability and regulatory review.

Excipient-minimized formulation

An excipient-minimized product could be positioned for hospitals seeking simpler compounding and lower excipient exposure. The formulation would rely on the inherent stability of pemetrexed dipotassium and robust container-closure protection.

This approach has commercial appeal but creates a narrower design space. If the potassium salt is hygroscopic or unstable in solution, the product may require more complex packaging or a less convenient dosage form.

What formulation patents could protect pemetrexed dipotassium?

The most commercially useful patent claims would likely cover the product architecture rather than the basic use of pemetrexed.

Potential claim categories include:

Claim category	Commercial value	Typical vulnerability
Pemetrexed dipotassium salt	Blocks direct use of the selected salt	Salt-selection obviousness and prior-art risk
Specific polymorph or crystalline form	Controls API sourcing and formulation consistency	Characterization and enablement requirements
Lyophilized composition	Protects excipient ratios and cake structure	Design-around through different excipients
Stable aqueous solution	Supports ready-to-use product	Stability data must be robust and reproducible
Defined pH and osmolality range	Protects product performance	Narrow claims may be easy to avoid
Reconstitution method	Protects preparation workflow	Limited value if alternative instructions work
Container-closure system	Protects packaging and stability	Packaging substitutions may avoid claims
Infusion-bag compatibility	Can protect hospital-use configuration	May be difficult to enforce without clear product evidence
Manufacturing process	Protects salt conversion, crystallization, or lyophilization	Process claims may be difficult to detect in the market

A salt patent is stronger when it demonstrates an unexpected technical advantage, such as materially improved stability, reduced impurity formation, lower reconstitution time, improved cake integrity, or lower manufacturing cost. Merely replacing sodium with potassium may face an obviousness challenge if the prior art discloses pharmaceutically acceptable alkali-metal salts.

Method-of-use claims are less likely to create meaningful current protection for the core oncology indications because pemetrexed use is established and the principal U.S. Alimta patent barriers have expired or reached their end-of-term periods.[2,7]

When did pemetrexed lose major U.S. exclusivity?

Alimta’s core composition-of-matter protection and later method-of-use protections have expired or reached their relevant end dates. The principal commercial loss of exclusivity occurred in the early 2020s as generic pemetrexed products entered the U.S. market.

Milestone	Approximate timing	Commercial effect
FDA approval of Alimta	2004	Established pemetrexed as an oncology product
Core composition protection	Expired in the 2010s	Opened the principal generic pathway
Vitamin supplementation and administration patents	Extended protection into the early 2020s	Delayed some generic launch strategies
Generic pemetrexed entry	Beginning in the late 2010s and accelerating thereafter	Reduced branded pricing power
Current market	Generic-dominated in many channels	Opportunity shifts to supply, formulation, and manufacturing efficiency

Lilly reported Alimta revenue of approximately $2.1 billion in 2019, demonstrating the size of the pre-generic revenue pool.[8] That revenue base supported multiple generic entrants but also created severe price pressure after loss of exclusivity.

Which companies compete in pemetrexed injection?

The competitive field includes branded and generic manufacturers such as Eli Lilly, Teva, Fresenius Kabi, Hikma, Dr. Reddy’s Laboratories, Accord Healthcare, and other regional suppliers, depending on jurisdiction and product availability.

Competition is based on:

• Reliable API supply.
• FDA-compliant sterile manufacturing.
• Vial sizes and dosing flexibility.
• Contracting with hospitals and group purchasing organizations.
• Shortage avoidance.
• Global registration coverage.
• Low-cost lyophilization.
• Delivery convenience.

A pemetrexed dipotassium product would not compete only on active ingredient price. It would need a measurable benefit in supply reliability, preparation time, stability, packaging, or geographic availability.

Are there Paragraph IV challenges involving pemetrexed?

Pemetrexed has been the subject of historical patent litigation and generic challenges involving Alimta patents, including disputes over the scope and timing of method-of-use protections.[7] The commercial significance of those disputes has largely declined as the principal patent terms have expired.

A new pemetrexed dipotassium ANDA could still face patent certification issues if the Orange Book contains relevant unexpired listings for the reference product or if the applicant’s proposed labeling overlaps a protected indication. The risk depends on:

• The specific listed patents at filing.
• Proposed labeling.
• Indication carve-outs.
• Dosage and administration language.
• Whether the product is submitted under an ANDA or 505(b)(2).
• The sponsor’s certification and notice strategy.

For a new dipotassium formulation, patent risk may shift from legacy Alimta patents to formulation, process, and salt patents owned by the applicant or third parties. A targeted freedom-to-operate review should focus on U.S., European, Japanese, Chinese, and Indian filings covering pemetrexed salts, crystalline forms, injectable compositions, and lyophilization processes.

Is pemetrexed dipotassium exposed to biosimilar competition?

No. Pemetrexed is a small-molecule chemical drug, not a biologic. Competitors would enter as generic or hybrid products rather than biosimilars.

The relevant market risks are:

• ANDA-based generic injection.
• 505(b)(2) reformulation.
• Regional generic products.
• Hospital-compounded alternatives where legally permitted.
• Contract-manufactured private-label products.

A dipotassium product could be differentiated from standard disodium generics, but it would still compete against the same active moiety and established clinical dosing.

What commercial opportunities exist for pemetrexed dipotassium?

Lower-cost API and dual-sourcing

A potassium salt may provide an alternative API manufacturing route if crystallization, isolation, yield, or impurity rejection is superior to the disodium route. The economic case depends on isolated yield, solvent recovery, drying time, impurity purge, and regulatory comparability.

Improved lyophilized presentation

A product with faster reconstitution, lower residual moisture, improved cake integrity, or extended shelf life could attract oncology hospitals and distributors. The benefit must be demonstrated in comparative handling studies.

Ready-to-use oncology supply

A ready-to-use presentation could reduce pharmacy compounding time and handling exposure. This is the clearest route to premium pricing, but it carries higher stability, packaging, and manufacturing costs.

Geographic expansion

Markets with limited access to pemetrexed disodium suppliers may support an alternative potassium-salt product, especially where local regulations permit a hybrid or abridged application. The highest-value jurisdictions are the United States, European Union, Japan, China, Canada, Australia, Brazil, and major Middle Eastern markets.

Contract manufacturing and licensing

A company with sterile fill-finish capacity could license a dipotassium formulation to an oncology-focused generic manufacturer. The most bankable licensing package would include:

• Validated API route.
• GMP manufacturing package.
• Stability data.
• Scale-up evidence.
• Container-closure qualification.
• Regulatory dossier.
• Patent filings with data supporting unexpected advantages.
• Territory-specific registration rights.

How strong is the patent estate for pemetrexed dipotassium?

The patent estate is potentially moderate if it covers a demonstrated formulation or manufacturing advantage. It is weak if it relies only on the existence of the potassium salt without evidence of unexpected performance.

A stronger portfolio would combine:

1. Composition claims for a defined dipotassium polymorph.
2. Lyophilized formulation claims.
3. Stability and reconstitution claims.
4. Manufacturing-process claims.
5. Container-closure claims.
6. Method claims limited to a differentiated administration system.

The portfolio should avoid relying on a single broad salt claim. Generic competitors could use pemetrexed disodium, another potassium-containing composition, or a different excipient system to avoid infringement.

What generic launch scenarios exist for pemetrexed dipotassium?

Launch scenario	Probability profile	Commercial result
Standard lyophilized vial	Most straightforward	Rapid price competition with disodium generics
Premium ready-to-use solution	More differentiated	Higher development burden and possible price premium
505(b)(2) reformulation	Potentially valuable	Longer development and regulatory timeline
Regional API-only supply	Lower regulatory burden	Limited margin unless manufacturing cost is superior
Hospital-focused private label	Moderate	Depends on supply contracts and sterile capacity
Combination with enhanced packaging or workflow	Differentiated	May support licensing and institutional sales

The lowest-risk path is a lyophilized injectable with a narrow excipient profile and a strong API supply advantage. The highest commercial upside is a ready-to-use product with validated stability and lower pharmacy labor requirements.

Key Takeaways

• Pemetrexed dipotassium is an alternative salt of pemetrexed, while Alimta and established U.S. generics use pemetrexed disodium.
• The most practical initial dosage form is a single-dose lyophilized vial.
• Mannitol, pH adjusters, sterile water, and sodium chloride remain the logical starting excipient system.
• A different salt may require salt-specific regulatory justification and may not qualify automatically as a routine ANDA generic.
• The strongest commercial differentiation would come from ready-to-use delivery, faster reconstitution, improved stability, or supply reliability.
• Legacy Alimta exclusivity has largely expired, so current value lies in formulation, manufacturing, and distribution advantages.
• Pemetrexed has generic rather than biosimilar competition.
• Salt, polymorph, formulation, process, and container-closure patents could support licensing, but basic salt claims face obviousness and design-around risks.
• The addressable market was substantial before generic erosion, with Alimta revenue of about $2.1 billion in 2019.
• A dipotassium product should be evaluated as a formulation and supply-chain opportunity, not as a simple substitution for pemetrexed disodium.

FAQs

Can pemetrexed dipotassium be substituted automatically for pemetrexed disodium?

No. Automatic substitution depends on FDA therapeutic-equivalence findings and the approved product labeling. A different salt should not be treated as interchangeable without regulatory approval.

Would potassium content create a major safety barrier?

Probably not at standard dose levels, but the potassium contribution must be quantified and labeled. Renal impairment, hyperkalemia risk, dilution conditions, and concomitant medicines require assessment.

Is a pemetrexed dipotassium ready-to-use bag commercially attractive?

Yes, if the product maintains long-term stability, supports validated infusion compatibility, and reduces oncology-pharmacy preparation steps. These requirements create a higher development burden than a lyophilized vial.

Can a company obtain a patent on pemetrexed dipotassium?

Potentially, but the strongest patent position would require a defined salt form, polymorph, formulation, or process with reproducible and non-obvious technical advantages.

What is the main manufacturing barrier?

The principal barrier is sterile injectable production combined with salt-specific control of crystallinity, moisture, impurities, reconstitution, and container-closure stability.

References

1. U.S. Food and Drug Administration. (2023). Alimta (pemetrexed for injection) prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant DNA origin: Guidance for industry.
4. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.
5. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products.
6. DailyMed. (2024). Pemetrexed for injection prescribing information. U.S. National Library of Medicine.
7. U.S. Court of Appeals for the Federal Circuit. (2017). Eli Lilly and Company v. Teva Parenteral Medicines, Inc., patent litigation concerning pemetrexed administration.
8. Eli Lilly and Company. (2020). 2019 annual report.